CD4 and graft versus host disease: This innovative treatment option is supported by mouse models: the group of Lim showed that MSC-derived EVs alleviates GvHD symptoms and increases survival which was associated with a significant increase in CD4+CD25+CD127low/− regulatory T cells [7].